• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Paromomycin derivatives of the formula wherein R1 represents a hydrogen or chlorine atom, and their pharmaceutically acceptable addition salts. Different methods of producing these derivatives starting from 4',6'-O-benzylidene-penta-N-benzyloxycarbonylparomomycin are also disclosed. The compounds (I) and their pharmaceutically acceptable acid addition salts are useful as active ingredient in therapeutical compositions and as antibiotics for the treatment of amoebic disentery, shigellosis and salmonellosis.
    公开号:SU1103796A3
    申请号:SU802931695
    申请日:1980-06-06
    公开日:1984-07-15
    发明作者:Баттистини Карло；Кассинелли Джузеппе；Франчески Джиованни；Мадзолени Розанна；Аркамоне Федерико
    申请人:Фармиталиа Карло Эрба С.П.А. (Фирма)；
    IPC主号:
    专利说明:

    I110
    This invention relates to the production of a new derivative of paromomycin, which possesses valuable pharmacological properties of the formula.
    and JU.J.-®.
     V --- r on nna.
     Prince;
    % Hg
    The aim of the invention is to obtain a new compound of an expanding range of means of affecting a living organism that exceeds the structural analogue paromomycin in biological activity (see table).
    This goal is achieved by synthesizing said compound based on known acylation reactions, obtaining B-alkyldithiocarbonate and reducing 1.
    The method for preparing the paromomycin derivative of formula (1) is ill 11 oJI / 1 (
    6, 3, 2, 5, 3, A-hydroxy-4, & -O-benzylidene-penta-M-benzyloxycarbonylparomomitsi is exposed to acetic anhydride in the presence of pyridine, followed by hydrolysis of the resulting hexa 0-acetyl-4 , 6 -0-benzylidene-penta-N-6enzylkyrbonylparomomycin vinegar} acid, at room temperature, by treatment of the obtained b -oxy derivative 6, C, 21 3I 4 -hexa-0-apetil-penta-N-benzoylcarbonylparomicin chlorine chloroimocine chloroylcarboxylic acid. benzoyl in dry pyridine at 0 ° and the b-benzyl derivative obtained is treated with sulfuric chloride in dry pyridine, or carbon disulfide, sodium hydroxide and methyl iodide, or (phenylthio) thiocarbonyl chloride in the presence of 4-dimethyl-aminopyridine, p. the subsequent reduction of the resulting derivative with tributyltin hydride under a nitrogen atmosphere in toluene at the boiling point of the solvent and in the presence of azobisisobutyronitrile, by hydrolysis with sodium mystylate and boiling with a refrigerator under reflux conditions.
    796S
    80% ethanol li presence of cyc-. logexane and 10% palladium on coal. Bilogic activity. 4 deoxyparomomycin develops; antibacterial actin vitro,
    Tests of the biological activity of the compound in vitro were carried out by serial dilution in liquid medium (nutrient broth. I Difco) and the minimum suppressant concentration (MIC) was determined after 24 hours incubation at 37 C. As can be seen from the table , 4-d, eoxyparo ;; 5 momicIn has a similar effect to paromomycin on antigioma-sensitive iggamma 5 and exhibits an increased activity against some resistant 20 strains of gram-negative bacteria. The minimum inhibitory concentration (µg / ml) of the compound () in comparison with paromomycin is presented in the table.
    Will 1. Production of hexa-O-acetyl-4, b-O-benzylidene-penta-fM-benzyloxycarbonate paromomycin.
    In 112 ml of pyridine, 11.1 g of 456-0-benzylidenepenent-N-beiGyloxycarbonylparomomycin (1) are dissolved in 56 ml of acetic anhydride. The reaction solution is left for three days at room temperature, and then I can be poured slowly into a stirred mixture of WATER and ice. After stirring for one hour, the resulting white solid was filtered, washed thoroughly with water and dissolved in methanol. After evaporation of the solvent, 12.7 g of hexa-O-acetyl-4, 6-0-benzylidenepenta-H-benzyloxycarbonylparomomycin are obtained.
    Melting point, 124-127. Wl 21.0
    Pm measure 2, Getting 6,3,
    -.I with -1 Hf /,
    ;, L 5 J, A-gksa-and-acetylpenta-N-benzyloxycarbonylparomomycin
    A solution containing 12.8 g of the compound obtained in Example 1 in 500 ml of acetic acid and 125 ml of water is left for 90 h at room temperature. The solvent is then evaporated, the residue is dissolved in methanol and the methanol is removed (optically repeated several times). The result is 11.6 g of the compound, the name of which is given in the title of Example 2. This compound is a solid amorphous substance. Melting point 116-119 °, 19.9 (with 0.537, CHC1.j). NMR Spectrum: (60 MHz, CDClj) shows the correct ratio of aromatic and acetyl protons (1.38) Example 3. Preparation of 6, 3, D 11 g / G: 2, 5, 3, 4-hex-0 -acetyl-6-0-benzoyl-penta-M-benzyloxycarbonylparomomycin. 10.1 g of the substance obtained in Example 2 are dissolved in 100 ml of dry pyridine and cooled to 0 °. A solution of 0.84 ml of benzoyl chloride in 2 ml of pyridine is then added slowly with stirring. The reaction mixture was kept at 0, controlling the course of the reaction by thin layer chromatography. After 43 hours from the start of the reaction, 0.42 benzoyl chloride in 1 ml of pyridine was added to the reaction solution. After 67 hours, the reagent was again added (0.2 ml of benzoyl chloride in 0.5 pyridine) and 96 hours after the reaction began the mixture is added with water and then extracted with chloroform. The chloroform extracts are washed with water, 2 M hydrochloric acid solution again with water, then with sodium bicarbonate solution and again with water. After drying the organic solution and removing the solvent (chloroform), 10.9 g of the substance are obtained. The crude (crude) product is purified on a column filled with silica gel. (0-2% methanol in chloroform is used as the solvent) Tate get 5.8 g of pure target product. Melting point 110-115. o / j 26.3 (c 1.096; CHCIj). Calculated,%: C 59.9; P 5.58; N 4.26,. Found,%: C 59.8; ri 5.77; N 4.19. Er and mep 4, Preparation of 6, 3, 5, 3, 4-hexa-0-acetyl-6-0-benzoyl 4-zpichlop-4-deoxypent-N-benzyloc. Sicarbonylparomomycin. 1 g of the compound obtained in Example 3 was dissolved in 15 ml of dry pyridine and 1.3 ml of sulfuryl chloride was added dropwise to the solution cooled to O. Thereafter, the reaction mixture was stirred at 0 ° C for 3 hours and at room temperature for 13 hours, then a large solvent 4acTiJ was removed in vacuo, and chloroform and water were added to the residue. After extraction with chloroform, the chloroform layer is washed with water, dried and the solvent is removed in vacuo. The crude product is purified by preparative thin-layer chromatography and reprecipitation of chloroform-ether hexane from a mixture. The result is 515 mg of the desired product in pure form. This compound has a Rt of 0.37 in the solvent system toluene - ethyl acetate 1 (by volume) and contains an atom in the molecule. chlorine (the starting material has Rf0.23). Melting point 105-115, 30.3 (c 1.012, CHC13). Calculated. %: C 59.29; H 5.46; C1 2.13; N 4.12. CgjHgoCINsOjo Found,%: C 58.38; H 5.41; C1 2.36; N 4.14, PRI me R 5. Getting 6, 3, 2; 5i 4 -hexa-0-acetyl-6-0-benzoyl-4-dioxypent-N-benzyloxycarbonylparomomycin. A solution of 400 mg of the compound obtained in Example 4 in 16 ml of toluene is heated to boiling under nitrogen and 0.8 ml of hydride- tributyl tin in 0.8 ml of toluene and 20 mg of azobisisobutyronitrile are added. After boiling the reaction mixture under reflux for 3 hours, the solvent was evaporated, and the solid residue was washed with n-hexane, dissolved in chloroform, and the resulting solution was added to a mixture of diethyl ether and n-hexane. As a result of precipitation, 385 mg of the title compound are obtained, with a frequency sufficient for subsequent reactions. In the solvent system toluene-e.type (1: 1 by volume) the compound has Rr 0.31. Melting point 125-130, Lcf-1 - 33.0 (c 1.116; CHC1 ;;). Calculated,%: C 60,54; N 4.30. CezHg N Ojo Found,%: C 59.90; And 5.59; N 4.30, Example 6. Preparation of 4-D1; .. Sipenta-A-benzyloxycarbonylparOg of tsina (7). 385 mg of compound 5 obtained in example 5, without further purification, are dissolved in 14 ml of a 0.05 N methanolic solution of sodium methylate and stirred at room temperature for 3 hours. After this, solid carbon dioxide and water are formed and the resulting solution evaporated to dryness. Water was added to the residue and the mixture was extracted several times with ethyl acetate. The combined organic extracts are washed with water and evaporated to give 205 mg of the crude (crude) product indicated above. Purification of the product was carried out by the method of preparative thin layer chromatography using chloroform-ethyl acetate-methanol solvent ratio of 40: 25: 9 (by volume) as eluent. 130 mg of the purely desired product are obtained, having Rr.0j22 (in the same solvent system, the torus is used as eluent), Melting point 125-130 G / s: - 41.0 (with 0.900 CHCIo). , Calculated,%: C 59.56; H 5.95; N 5, 5 K C. ,, Found,%: C 58.74, H 5.78, N5.36. Example 7. Preparation of 4-deo-siparomomycin. To a solution of 130 mg of the compound obtained in Example 6 in 16 ml of 80% methanol was added 1 ml of cyclohexane and 20 mg of 10% palladium on coal. The resulting mixture was heated under reflux for 1.5 hours, then filtered and the solvent evaporated in vacuo. 50 mg of a solid residue was obtained. A swarm of (crude) product is purified on a column filled with CG 50 sorbent (in the NH4 form, 100-200 mesh), 21 mg of the compound indicated above is obtained in its pure form with a melting point of 175-180 (with decomposition). The product is homogenous on a plate coated with a thin layer of sorbent (two-dimensional chromatogram in the solvent system 28% amm1- {ak; butanol: ethanol: water 5: 8; 10; 7 by volume and has Kg, i.e. slightly above this value for Lipidomipine B (3-deoxyparomidine), which has R, 0, 30. The product, which is your own free base, is converted to sulfate by adding 0.2 m of sulfuric acid solution to a pH of 6.4. Melting point (with times; 230) (for sulfate), 58 (with 1.115; M-jO, for sulfate). Elemental analysis (sulfate form) for 5/2 HjSO. Calculated,% : C 32.70; AND 5.96; N 8.29. Found: C 33.51; H 6.47; N 7.83. Example 8: Preparation 6, 3, ((/ g l I / IGf f. 2,5, 3, 4-hexa-0-adyl-6-benzoyl-4-0- (methylthio) thiocarbonyl 1pen-Ta-N-benzyloxycarbonylparomomycin 0.28 ml of 5N sodium hydroxide solution added dropwise to an ice-cooled solution of 400 mg of the compound obtained in Example 3 and 0.4 ml of carbon disulfide in 3 ml of dimethyl sulfoxide. The resulting mixture is stirred for 20 minutes at 0%. Then, while cooling, 0.6 ml of methyl iodide was added to the mixture and the reaction mixture was stirred at room temperature for 30 minutes. The excess volatile reagents are removed under reduced pressure and, after adding water to the residue, the solution is extracted with TiToT with ethyl acetate .. The extracts are washed with sodium chloride solution, then with water, then the organic layer is dried and carbonated. A mixture of three compounds is obtained, each of which has Rr 0.35; 0,42 and 0,53, respectively, in the solvent system toluene: ethyl acetate 1: 1 (by volume). The compound, which represents the wasp; {the residual part, and has the lowest R value, was prepared by the preparation of thin layer chromatography. 125 mg of the compound indicated is obtained in purified gi1de. Example 9 Preparation of 6, 3, 5, 3, 4-hexa-0-acetyl-6-0-benzoyl-4-deoxypen. A-H-benzyloxycarbonylparomomycin. The reaction is carried out in a nitrogen atmosphere. A solution of 0.4 ml of tributyl tin hydride in 0.8 ml of toluene and 10 mg of azobisiobutyronitrile was added to a boiling raster of 125 mg of the compound Prepared in Example & 8 ml of dry toluene. After boiling the mixture for 2 hours under reflux, the reaction mixture is treated according to Example 5. 70 mg of product are obtained that is no different from the product described in Example 5. 70 mg of product is obtained that is no different from that described in Example 5.
    Example 10. Getting 6, 3, 2 5 4 -hexa-0-acetyl-b-0-benzoyl-4-0- (phenylthio) thiocarbonyl-penta-M-benzyloxycarbonylparomomycin.
    To a cooled to 0 ° solution of 1 g of the compound obtained in Example 3 in 20 ml of dry pyridine was added 4 g of (phenylthio) thiocarbonyl chloride and 100 mg of 4-dimethyl-aminopyridine. The reaction mixture was stirred at room temperature for 5 days. Thereafter, water and ice are added to the mixture and extracted with chloroform. The chloroform extracts are washed with water, 2N hydrochloric acid, water, sodium bicarbonate solution and again with water. TCW organic solution dried
    Mr. evaporated. The residue is purified on a column filled with silica gel; a mixture of solvents toluene: ethyl acetate in the ratio 1: 1 (by volume) is used as eluent. Further purification is achieved by using the method of preparative thin layer chromatography and reprecipitation of chloroform ether-hexane from a mixture. As a result of the purification, 600 mg of the compound indicated above are obtained. I The product is chromatographically homogeneous and has Rg 0.34 in the solvent system toluene ethyl acetate (1: 1 by volume).
    Example Preparation of 6, 3, 2 5, 3 4 -xxx-0-acetyl-6-0-benzoyl-4-deoxypenta-G-benzoyloxycarbonylparomomycin. .
    To a boiling solution of 320 mg, co,. of the compound obtained in Example tO, in 13 ml of dry toluene, 2 ml of tributyltin hydride diluted in 4 ml of toluene and 30. mg of azobisisobutyronntril are added. The reaction is carried out in a nitrogen atmosphere. After boiling the reaction mixture under reflux for 2 hours, it is bathed as described in Example 5. As a result, 50 mg of the compound indicated above is obtained.
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING A PAROMOMYCIN DERIVATIVE OF FORMULA of the formula (1) characterized in that. 6.3 ', 2', '5''3;4'-hydroxy-4,6-0-6 benzylidene-penta-N-benzyloxycarbonylparomomycin is exposed to acetic anhydride in the presence of pyridine, followed by hydrolysis of the obtained hexa-O-acetyl-4 1 , 6 ', 0-benzylidene-penta-M- benzylcarbonylparomomycin with acetic acid at room temperature by treating the resulting 6-hydroxy derivative 6.3 ', 2 i 5 ^ 3 ^ 4-hexa-0-acetyl-penta-M-benzoylcarbonylparomomycin with benzoyl chloride in dry pyridine at 0 ° and the resulting 6-benzoyl derivative treated with sulfuryl chloride in dry pyridine, or carbon disulfide, hydro sodium hydroxide and methyl iodide, or (phenylthio) thiocarbonyl chloride in the presence of 4-dimethylaminopyridine, followed by reduction of the resulting tributyltin hydride derivative in a nitrogen atmosphere in toluene at the boiling point of the solvent and in the presence of azobisisobutyronitrile under reflux with sodium chloride. % ethanol in the presence of cyclohexane and 10% palladium on charcoal.
    J103796
    1103 796
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0041355B1|1983-02-23|Novel erythromycin compounds
    US5010099A|1991-04-23|Discodermolide compounds, compositions containing same and method of preparation and use
    SU1103796A3|1984-07-15|Process for preparing derivative of paromomycin
    SU893135A3|1981-12-23|Method of preparing derivatives of 4-desacetylvincaleucoblastin-c-3-carboxyhydrazide
    KR100559817B1|2006-03-10|Sphingosine analogues
    CZ54495A3|1997-08-13|Process for preparing and/or purification of clavulanic acid
    FR2776292A1|1999-09-24|Novel cephalotaxane derivatives with a side chain
    RU1771477C|1992-10-23|Method for production of amikacine as sulfate salt
    SU1547707A3|1990-02-28|Method of producing trans-ethyl-1,2,3,4-tetrahydro-6,7-methylenedioxy-4-oxo-1|naphthalene-2-carboxylate
    EP0060999B1|1985-08-21|Galactopyranosides, process for their preparation and their use as antigens or immuno absorbents
    EP0080819A1|1983-06-08|11-0-Alkylerythromycin A derivatives
    CH627475A5|1982-01-15|Process for preparing cephem compounds as intermediates for the synthesis of cephalosporins
    FR2461717A1|1981-02-06|PROCESS FOR OBTAINING ANTIBIOTIC ESTERS FROM THE GROUP OF POLYENE MACROLIDES AND THEIR N-SUBSTITUTED DERIVATIVES
    DE2453649C3|1982-01-21|Process for the preparation of coformycin and intermediates for its preparation
    SU680650A3|1979-08-15|Method of obtaining 7b-/d-2-amino-2-|-acetylamino/-3-chlor-3-cephem-4-carbolic acid or salts thereof
    SU776562A3|1980-10-30|Method of preparing anthracyclines
    JP4770032B2|2011-09-07|Sheatan derivative
    US5096905A|1992-03-17|Basic cleavage products of elaiophylin and elaiophylin derivatives and use thereof
    SU1074405A3|1984-02-15|Method of producing urazole derivatives
    CH640520A5|1984-01-13|Cyclosporin derivatives
    US4174451A|1979-11-13|2-Furyl-|-carbinol
    US6005119A|1999-12-21|Process for preparing pyrrolidine derivatives
    Yoshikawa et al.1989|Pahutoxin: synthesis and determination of its absolute configuration
    RU2091388C1|1997-09-27|Method of synthesis of steroid esters
    SU857138A1|1981-08-23|Method of preparing 2,4-di-|-6,7-di-|-1,3,5,8-tetramethylporphirones
    同族专利:
    公开号 | 公开日
    DK246180A|1980-12-08|
    AU5895580A|1980-12-11|
    JPS55164697A|1980-12-22|
    IE801163L|1980-12-07|
    FI69082B|1985-08-30|
    FI801769A|1980-12-08|
    FI69082C|1985-12-10|
    EP0021150A1|1981-01-07|
    IL60217A|1983-11-30|
    AU534470B2|1984-02-02|
    BE883686A|1980-12-08|
    EP0021150B1|1983-05-18|
    IL60217D0|1980-09-16|
    FR2458556A1|1981-01-02|
    IT1201934B|1989-02-02|
    FR2458556B1|1983-07-08|
    IE50057B1|1986-02-05|
    AT3429T|1983-06-15|
    US4337248A|1982-06-29|
    ZA803031B|1981-05-27|
    CA1137982A|1982-12-21|
    DE3063288D1|1983-07-07|
    CS226412B2|1984-03-19|
    IT8022594D0|1980-06-06|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3920628A|1972-10-24|1975-11-18|Schering Corp|2{41 -Deoxyaminoglycosides and 2{41 -epi-amino-3{41 -desamino derivatives thereof, methods for their manufacture and novel intermediates useful therein|
    SE402777C|1972-12-29|1979-01-25|Takeda Chemical Industries Ltd|METHODS OF PRODUCING AMINOGLYCOSIDE ANTIBIOTICS OF 3 'AND / OR 5' '- DIOXINEOMYCIN TYPE, 3'- AND / OR 2' '- DIOXICANAMYCIN TYPE OR 3' '- DIOXISTRYPTOMYCINTYPE|
    US4051315A|1974-11-13|1977-09-27|Bristol-Myers Company|6"-Deoxykanamycin B and 6"-deoxytobramycin|
    JPS5850235B2|1974-12-11|1983-11-09|Meiji Seika Co|
    US4247687A|1979-06-12|1981-01-27|Farmitalia Carlo Erba S.P.A.|Aminoglycoside antibiotic derivatives and process for their preparation|US5470836A|1988-04-29|1995-11-28|Farmitalia Carlo Erba S.R.L.|Paromomycin or its derivatives or salts thereof in combination with sodium stirogluconate for parenteral treatment of human parasitic diseases|
    US7829543B2|2003-01-07|2010-11-09|Paratek Pharmaceuticals, Inc.|Substituted polyamines as inhibitors of bacterial efflux pumps|
    JP5256043B2|2005-12-02|2013-08-07|アイシスファーマシューティカルズ，インコーポレーテッド|Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents|
    EP2148884A1|2007-04-10|2010-02-03|Achaogen, Inc.|Antibacterial 1,4,5-substituted aminoglycoside analogs|
    WO2010030704A2|2008-09-10|2010-03-18|Achaogen, Inc.|Antibacterial aminoglycoside analogs|
    WO2010030690A1|2008-09-10|2010-03-18|Isis Pharmaceuticals, Inc.|Antibacterial 4,6-substituted 6', 6" and 1 modified aminoglycoside analogs|
    WO2010042851A1|2008-10-09|2010-04-15|Achaogen, Inc.|Antibacterial aminoglycoside analogs|
    WO2010042850A1|2008-10-09|2010-04-15|Achaogen, Inc.|Antibacterial aminoglycoside analogs|
    CN102596981A|2009-10-09|2012-07-18|尔察祯有限公司|Antibacterial aminoglycoside analogs|
    WO2011044538A1|2009-10-09|2011-04-14|Achaogen, Inc.|Antibacterial aminoglycoside analogs|
    WO2012067978A1|2010-11-17|2012-05-24|Achaogen, Inc.|Antibacterial amiinoglycoside analogs|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB7919778|1979-06-07|
    [返回顶部]